Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target reduced by Morgan Stanley from $300.00 to $240.00 in a report issued on Friday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.
ALNY has been the subject of a number of other reports. Citigroup decreased their price objective on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Zacks Research cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. The Goldman Sachs Group dropped their price target on Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating on the stock in a research note on Friday. Raymond James Financial cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their target price for the stock from $420.00 to $315.00 in a research note on Friday. Finally, Sanford C. Bernstein cut Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $376.00 to $199.00 in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $317.95.
View Our Latest Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Price Performance
NASDAQ ALNY opened at $165.00 on Friday. Alnylam Pharmaceuticals has a fifty-two week low of $163.30 and a fifty-two week high of $479.79. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The firm has a market cap of $22.10 billion, a P/E ratio of 8.57 and a beta of 0.43. The stock’s 50-day moving average is $236.49 and its two-hundred day moving average is $286.19.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.90 EPS. On average, analysts anticipate that Alnylam Pharmaceuticals will post 6.58 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Toth Financial Advisory Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $25,000. Burkett Financial Services LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $37,000. CoreCap Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 134 shares during the period. Keating Financial Advisory Services Inc. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $42,000. Finally, Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $48,000. 92.97% of the stock is currently owned by institutional investors.
More Alnylam Pharmaceuticals News
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
- Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
- Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
- Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
- Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.
Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
